548 Episodes

  1. Leveraging Technology to Empower Patients and Decentralize Clinical Trials

    Published: 10/20/2022
  2. Equipping The Next-Generation Rare Disease Patient Advocate

    Published: 10/13/2022
  3. How a Family Raced from Diagnosis to Experimental Gene Therapy in Three Years

    Published: 10/6/2022
  4. How One Advocate Went from Losing His Hearing to Being Heard

    Published: 9/29/2022
  5. Building a Pipeline of Therapies to Treat Rare Mineralization Disorders

    Published: 9/22/2022
  6. Advancing an Oral Alternative to Infused and Injected Therapies for HAE

    Published: 9/15/2022
  7. Embracing the Promise of Patient-Centered Biotechnology

    Published: 9/8/2022
  8. Learning to Live with Loss

    Published: 9/1/2022
  9. Using Cryptocurrency to Tap into the Wisdom of Crowds

    Published: 8/25/2022
  10. A Therapy for a Rare Neurodegenerative Disease Moves Towards Regulatory Review

    Published: 8/18/2022
  11. Transforming the Treatment of Neuromuscular Diseases with Next-Gen Oligonucleotides

    Published: 8/11/2022
  12. Teaching the Immune System to Let Medicines Do Their Job

    Published: 8/4/2022
  13. Designing Clinical Trials with the Patient in Mind

    Published: 7/28/2022
  14. Keeping Clinical Trials Running Smoothly

    Published: 7/21/2022
  15. A Vision for Patient-Centric Gene Therapy Development

    Published: 7/14/2022
  16. Using Genetic Testing to Address Disparities in Care for Kidney Disease

    Published: 7/7/2022
  17. Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development

    Published: 6/30/2022
  18. A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company

    Published: 6/16/2022
  19. Targeting Regulatory RNA to Upregulate Gene Expression to Treat Rare Diseases

    Published: 6/9/2022
  20. Developing a New Approach to Treat Rare, Autoimmune Conditions

    Published: 6/2/2022

8 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.